REPLIGEN CORP Common Stock, Capital Shares Reserved for Future Issuance
REPLIGEN CORP (RGEN) had Common Stock, Capital Shares Reserved for Future Issuance of 4.01 million shares as of 2013-12-31, per its 10-K filed 2016-02-25.
Discontinued › Notes
us-gaap:CommonStockCapitalSharesReservedForFutureIssuance · last filed 2016-02-25
- 2013-12-31: Common Stock, Capital Shares Reserved for Future Issuance 4.01M shares; Common Stock, Capital Shares Reserved for Future Issuance as first filed 2.79M shares.
- 2012-12-31: Common Stock, Capital Shares Reserved for Future Issuance 3.89M shares.
| Period end | Common Stock, Capital Shares Reserved for Future Issuance | Common Stock, Capital Shares Reserved for Future Issuance as first filed |
|---|---|---|
| 2013-12-31 | 4.01M shares 10-K · filed 2016-02-25 | 2.79M shares 10-K · filed 2014-03-14 |
| 2012-12-31 | 3.89M shares 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |